High Throughput Screening Markets 2027–2031

High Throughput Screening Markets: Market Forecast, Competitive Landscape, Technology and World Metropolitan Area Market Sizes, 2027–2031

Global forecasts by product, screening technology, application, assay format and end user, for 14 countries and regions and 237 metropolitan areas, with 40 company profiles. Detection instruments, liquid handling and automation, assay kits and consumables, compound libraries, software and AI, and screening services. First edition.

See the Table of Contents. GET the Free Sample of this Report.

Many organizations subscribe to all or some of our reports. You may already have free access to this report. FIND out Here.

Our Take

The screen goes virtual. High throughput screening was the industrial heart of drug discovery for thirty years: robots, 384- and 1536-well plates and libraries of a few million compounds. That physical machine is now mature, and the value is moving from robots to algorithms, as AI searches billions of virtual compounds before a plate is touched. The market grows from $8,600.0 million in 2026 to $12,300.0 million in 2031, at 7.4% a year.

Market Size 2026: USD $8,600M Market Size 2031: USD $12,300M CAGR: 7.4%

Situation Analysis: what is really happening

• The screen goes virtual. In Silico & AI Virtual Screening rises from 5.5% to 8.7% of the market at 17.7% a year, the fastest technology. NVIDIA and Lilly opened a co-innovation AI lab and Isomorphic Labs raised about $2.1 billion.
• From robots to algorithms. Software & AI is the fastest-growing product line at 16.3% a year, rising from 7.6% to 11.3% of the market, while Detection Instruments grow only 4.8% a year.
• Smaller and smarter. Ultra-Miniaturised & Microfluidic screening grows 12.0% a year as DNA-encoded libraries pool billions of compounds in one tube.
• Big pharma bets on AI. Takeda signed an AI discovery deal with Iambic worth more than $1.7 billion and Thermo Fisher partnered with OpenAI.
• The CROs reshape. CROs & Screening Service Providers grow 9.1% a year, while Charles River sold European discovery sites to IQVIA and Evotec restructured.
• China leads growth. China is the fastest-growing country at 14.0% a year.

Company Analysis: who is positioned, who is exposed

• Revvity, Thermo Fisher Scientific, Danaher (Molecular Devices, Beckman Coulter, SCIEX, Genedata), Agilent, Tecan, Hamilton, Bruker and Promega: The tools majors.
• HighRes Biosolutions, Azenta, SPT Labtech, Formulatrix, Biosero, BMG Labtech, Corning and Greiner Bio-One: Automation, detection and plates.
• Enamine, ChemDiv, ChemBridge, Life Chemicals, Specs, HitGen, X-Chem and Vipergen: Compound and DNA-encoded libraries.
• Schrödinger, Recursion, Isomorphic Labs, Insilico Medicine, Iambic, XtalPi, Dotmatics and NVIDIA: Software and AI drug discovery.
• Charles River, Evotec, WuXi AppTec, Pharmaron, Eurofins Discovery, Reaction Biology, BioAscent and Domainex: The screening CROs.

In all, 40 company profiles, each one to two pages with a fact box covering website, headquarters, ownership, revenue, employees and key products.

Questions this report answers

• How large is the high throughput screening market, and how fast will it grow?
• How fast is AI and virtual screening growing, and will computation replace the physical screen?
• How do instruments, automation, reagents, libraries, software and services compare?
• Which screening technologies and assay formats are gaining share?
• What do CRO consolidation, BIOSECURE and AI partnerships mean for suppliers?
• How large is each country market, and which metropolitan areas lead?

What's inside

• 362 pages, 23 chapters, 113 tables and 52 figures
• Forecasts for 2027–2031 from a 2026 base year, by product, screening technology, application, assay format and end user, for 14 countries and regions
• Market sizes for 237 world metropolitan areas in 2026 and 2031, with the top 30 and fastest-growing metros
• How high throughput screening works; products, screening technologies, applications and assay formats; end users and business models; technology trends in AI, automation, miniaturisation and lab-in-the-loop; AI and virtual screening
• Regulation, standards and data; 10 market-moving developments; competitive landscape, SWOT, Porter's Five Forces and strategic recommendations
• 40 company profiles
• Download the Table of Contents (PDF)

Who buys this report

• Instrument, automation and reagent companies: size target segments, plan for AI and miniaturisation, and assess partners and acquisitions.
• Library and DEL providers, and AI drug discovery companies: size the opportunity and position against the physical screen.
• Pharma, biotech and CROs: benchmark screening spend and outsourcing.
• Investors: assess AI discovery, consolidation and growth.

Use independent research that makes you the expert. Your credit card order sends the report to your inbox instantly. Check all your licensing options, but don't worry: your order is available as a credit if you wish to upgrade.

See the Table of Contents. GET the Free Sample of this Report.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. His education includes:

Finance for Senior Executives - Harvard Business School

Market Research - Burke Institute

M.B.A. (Finance and Policy) - University of British Columbia

B.Sc. (Chemistry) - University of British Columbia

He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years.